[go: up one dir, main page]

DK2483278T3 - Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer - Google Patents

Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer

Info

Publication number
DK2483278T3
DK2483278T3 DK10757213.3T DK10757213T DK2483278T3 DK 2483278 T3 DK2483278 T3 DK 2483278T3 DK 10757213 T DK10757213 T DK 10757213T DK 2483278 T3 DK2483278 T3 DK 2483278T3
Authority
DK
Denmark
Prior art keywords
relations
cancer
treatment
pi3k inhibitor
benzoxazepin
Prior art date
Application number
DK10757213.3T
Other languages
English (en)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Robert Heald
Timothy Heffron
Mark Jones
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Adrian J Folkes
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2483278(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2483278T3 publication Critical patent/DK2483278T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK10757213.3T 2009-09-28 2010-09-27 Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer DK2483278T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (en) 2009-09-28 2010-09-27 Benzoxazepin pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
DK2483278T3 true DK2483278T3 (da) 2014-01-13

Family

ID=43037239

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10757213.3T DK2483278T3 (da) 2009-09-28 2010-09-27 Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer

Country Status (31)

Country Link
US (7) US8242104B2 (da)
EP (3) EP2845592A1 (da)
JP (2) JP5540101B2 (da)
KR (1) KR101428346B1 (da)
CN (2) CN104744491B (da)
AR (1) AR078187A1 (da)
AU (1) AU2010299816C1 (da)
BR (1) BR112012006807A2 (da)
CA (1) CA2772691C (da)
CL (1) CL2012000754A1 (da)
CO (1) CO6491026A2 (da)
CR (1) CR20120121A (da)
DK (1) DK2483278T3 (da)
EC (1) ECSP12011755A (da)
ES (2) ES2570569T3 (da)
HR (1) HRP20140229T1 (da)
IL (2) IL217558A (da)
MA (1) MA33531B1 (da)
MX (1) MX2012003591A (da)
MY (2) MY184074A (da)
NZ (1) NZ597833A (da)
PE (1) PE20121025A1 (da)
PL (1) PL2483278T3 (da)
PT (1) PT2483278E (da)
RS (1) RS53164B (da)
RU (2) RU2654068C1 (da)
SG (1) SG10201405049RA (da)
SI (1) SI2483278T1 (da)
TW (1) TWI423980B (da)
WO (1) WO2011036280A1 (da)
ZA (1) ZA201202199B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025824B1 (ru) 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
RS53164B (sr) * 2009-09-28 2014-06-30 F. Hoffmann-La Roche Ag Jedinjenja benzoksazepin pi3k inhibitora i njihovo korišćenje u lečenju raka
PE20140918A1 (es) 2009-09-28 2014-08-06 Hoffmann La Roche Compuestos de benzoxepina inhibidores de la pi3k
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
JP6001635B2 (ja) * 2011-03-21 2016-10-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＰＩ３Ｋｐ１１０δに選択的なベンゾオキサゼピン化合物及び使用方法
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (da) * 2011-07-01 2018-04-28
PT4241849T (pt) 2011-10-14 2024-10-30 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
BR112014019209A2 (pt) * 2012-02-17 2017-07-04 Hoffmann La Roche compostos tricíclicos e métodos de uso para os mesmos
SG10201706196XA (en) 2012-06-08 2017-08-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
EP2882757B1 (en) * 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
CN108929333A (zh) 2013-03-13 2018-12-04 豪夫迈·罗氏有限公司 制备苯并氧氮杂*化合物的方法
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR101902664B1 (ko) * 2013-12-16 2018-09-28 에프. 호프만-라 로슈 아게 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도
MX2016011636A (es) 2014-03-13 2016-12-12 Hoffmann La Roche Combinaciones terapeuticas con moduladores de receptor de estrogeno.
AR103598A1 (es) 2015-02-02 2017-05-24 Forma Therapeutics Inc Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
CN114057765A (zh) 2015-02-02 2022-02-18 瓦洛健康股份有限公司 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016174616A1 (en) * 2015-04-30 2016-11-03 Novartis Ag Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CA2981159A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
CN112047960B (zh) 2015-07-02 2024-08-02 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
EP3317283B1 (en) * 2015-07-02 2019-04-03 H. Hoffnabb-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN108349996B (zh) * 2015-09-08 2021-01-08 豪夫迈·罗氏有限公司 三环pi3k抑制剂化合物及其使用方法
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109982999A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 新的5-取代的咪唑基甲基衍生物
SG10201913961PA (en) 2016-12-15 2020-03-30 Hoffmann La Roche Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino) propanamide
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
PL3615541T3 (pl) * 2017-04-28 2025-06-23 F. Hoffmann-La Roche Ag Postaci polimorficzne i postaci stałe (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3- ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanoamidu i sposoby wytwarzania
WO2019084459A1 (en) * 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
CN110785423B (zh) * 2018-05-30 2022-07-26 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
IL292592A (en) * 2019-11-04 2022-07-01 Betta Pharmaceuticals Co Ltd Imidazoline compound, process for its preparation and use
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
US20230014383A1 (en) * 2019-11-25 2023-01-19 Shanghai Hansoh Biomedical Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
WO2022233263A1 (zh) * 2021-05-03 2022-11-10 山东轩竹医药科技有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
IL308459A (en) 2021-05-13 2024-01-01 Betta Pharmaceuticals Co Ltd A polymorph of an imidazolidinone compound, its preparation method and use
EP4347574A1 (en) 2021-05-28 2024-04-10 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
WO2024104435A1 (zh) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (zh) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 一种稠环化合物及其制备和应用
WO2025237374A1 (zh) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 PI3Kα抑制剂及其制备方法和医药用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
FI943948A7 (fi) * 1992-12-28 1994-08-26 Eisai Co Ltd Heterosykliset hiilihappojohdannaiset
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5985799A (en) * 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
WO2001064675A1 (en) 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
HUP0304047A2 (hu) 2001-02-02 2004-04-28 Pharmacopeia, Inc. 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC kemokin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
EP1530565A1 (en) * 2002-07-19 2005-05-18 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
MXPA05008400A (es) * 2003-02-07 2005-10-05 Warner Lambert Co Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos.
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
US7632833B2 (en) * 2004-07-01 2009-12-15 Merck & Co., Inc. Mitotic kinesin inhibitors
RU2403258C2 (ru) * 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
US20080026171A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (PLA) and Ethylene Vinyl Acetate (EVA)
CA2659956C (en) 2006-08-04 2016-01-05 Lewis C. Cantley Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
MY147780A (en) * 2006-12-29 2013-01-31 Abbvie Deutschland Carboxamide compounds and their use as calpain inhibitors
CN101868254B (zh) 2007-09-19 2013-08-21 加利福尼亚大学董事会 免疫激活和选定癌症成像所用的正电子发射断层照相术探针
KR101626996B1 (ko) * 2008-03-31 2016-06-02 제넨테크, 인크. 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법
US8653097B2 (en) * 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
PE20140918A1 (es) * 2009-09-28 2014-08-06 Hoffmann La Roche Compuestos de benzoxepina inhibidores de la pi3k
RS53164B (sr) * 2009-09-28 2014-06-30 F. Hoffmann-La Roche Ag Jedinjenja benzoksazepin pi3k inhibitora i njihovo korišćenje u lečenju raka

Also Published As

Publication number Publication date
AU2010299816B2 (en) 2015-11-12
AR078187A1 (es) 2011-10-19
EP2711368B1 (en) 2016-03-23
JP2013505917A (ja) 2013-02-21
IL217558A (en) 2015-06-30
BR112012006807A2 (pt) 2020-11-03
SI2483278T1 (sl) 2014-03-31
KR101428346B1 (ko) 2014-08-07
CA2772691C (en) 2017-10-03
US20110076292A1 (en) 2011-03-31
CR20120121A (es) 2012-06-01
CN104744491A (zh) 2015-07-01
US20140058098A1 (en) 2014-02-27
US20130079331A1 (en) 2013-03-28
IL239081A0 (en) 2015-07-30
JP5625101B2 (ja) 2014-11-12
RS53164B (sr) 2014-06-30
US20170081341A1 (en) 2017-03-23
ECSP12011755A (es) 2012-05-30
MX2012003591A (es) 2012-04-19
PL2483278T3 (pl) 2014-05-30
MY160064A (en) 2017-02-15
US8242104B2 (en) 2012-08-14
EP2483278B1 (en) 2013-12-25
KR20120065431A (ko) 2012-06-20
ZA201202199B (en) 2013-01-30
RU2600927C2 (ru) 2016-10-27
US20140288047A1 (en) 2014-09-25
IL239081B (en) 2018-05-31
US8586574B2 (en) 2013-11-19
NZ597833A (en) 2014-01-31
TWI423980B (zh) 2014-01-21
PE20121025A1 (es) 2012-08-06
IL217558A0 (en) 2012-02-29
CL2012000754A1 (es) 2012-09-07
ES2570569T3 (es) 2016-05-19
US20160052933A1 (en) 2016-02-25
HRP20140229T1 (hr) 2014-04-11
WO2011036280A1 (en) 2011-03-31
US9198918B2 (en) 2015-12-01
EP2483278A1 (en) 2012-08-08
EP2711368A1 (en) 2014-03-26
TW201127844A (en) 2011-08-16
US9670228B2 (en) 2017-06-06
MA33531B1 (fr) 2012-08-01
JP5540101B2 (ja) 2014-07-02
US20120244149A1 (en) 2012-09-27
PT2483278E (pt) 2014-03-05
RU2012117398A (ru) 2013-11-10
CN102762576B (zh) 2015-04-22
US9546178B2 (en) 2017-01-17
CO6491026A2 (es) 2012-07-31
US8785626B2 (en) 2014-07-22
CN104744491B (zh) 2017-07-11
EP2845592A1 (en) 2015-03-11
JP2014070075A (ja) 2014-04-21
AU2010299816C1 (en) 2018-02-01
RU2654068C1 (ru) 2018-05-16
SG10201405049RA (en) 2014-10-30
MY184074A (en) 2021-03-17
US8343955B2 (en) 2013-01-01
AU2010299816A1 (en) 2012-02-02
ES2444779T3 (es) 2014-02-26
CA2772691A1 (en) 2011-03-31
HK1211929A1 (en) 2016-06-03
CN102762576A (zh) 2012-10-31
HK1174629A1 (en) 2013-06-14

Similar Documents

Publication Publication Date Title
DK2483278T3 (da) Benzoxazepin pi3k-inhibitorforbindelser og deres anvendelse i behandlingen af cancer
DK2473510T3 (da) Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2342233T3 (da) Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer
DK2127652T3 (da) Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
BRPI1011505A2 (pt) formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2437783T3 (da) Behandling af acinetobacter med alginatoligomerer og antibiotika
HRP20160551T8 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
EP2249854A4 (en) IMPROVED TREATMENT AND PROPHYLAXIS
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
DK2440253T3 (da) Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
BR112012005774B8 (pt) uso de um inibidor de quinase antiangiogênico no tratamento de câncer
DK2297106T3 (da) Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
DK2536748T3 (da) Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
HRP20170936T1 (hr) Alkilamido spojevi i njihova uporaba
DK2470202T3 (da) Clostridium-neurotoksiner til anvendelse i behandling af præmatur ejakulation
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
IL214349A (en) Preparations for the treatment of cancer and the use of cellulose energy inhibitors to create them